DCs activate antigen-specific CD8 + T cells that migrate to tissues where parasites accumulate, such as the lung, liver and brain, and there cause multi-organ tissue damage by cytolytic mechanisms leading to experimental cerebral malaria 12 . Whether similar immune-mediated mechanisms of disease pathogenesis occur in humans has been controversial, and the debate has not been assisted by the overinterpretation of data from experimental models and unrealistic claims of clinical relevance. The results from Guermonprez et al. 3 in infected children with severe disease provide the first real evidence to suggest that activated CD8 + T cells may be involved in the pathogenesis of severe malaria in humans and provide a strong argument for further work in this area; in particular, studies examining autopsy material to see whether activated CD8 + T cells are located in tissues damaged during severe malaria would be informative. If reasonable evidence can be found for CD8 + T cell involvement in human severe malaria syndromes, then these cells, as well as their cytolytic products, could be targeted for therapeutic advantage.
Severe malaria still accounts for far too many deaths, and the causal mechanisms leading to disease and death are likely to be heterogeneous. Therefore, by better understanding these processes, we can improve disease diagnosis and aid development of appropriate therapeutic interventions to supplement existing antiparasitic drug treatment regimes. This will require a clear understanding of pathogen-sensing pathways and their roles in driving host immune responses during malaria, so that pathogenic mechanisms can be targeted without impeding the development of crucial antiparasitic immunity.
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Glucagon's yin and yang effects on hepatic glucose production

Dale S Edgerton & Alan D Cherrington
New insights into the actions of the hormone glucagon are provided by a recent study in rodents, which shows that glucagon can suppress hepatic glucose production by acting through the mediobasal hypothalamic region of the brain. This central regulatory mechanism is impaired in rats fed a high-fat diet, suggesting that hypothalamic glucagon resistance may be relevant to the hyperglycemia observed in obesity, diabetes or both (pages 766-772). Surprising new evidence suggests that glucagon, a peptide hormone secreted by pancreatic alpha cells, inhibits hepatic glucose production through effects on the brain, in addition to its well-known direct stimulatory effect on the liver. In this issue of Nature Medicine, Mighiu et al. 1 provide data from rodent studies showing that glucagon suppresses hepatic glucose production through actions mediated by the mediobasal hypothalamus (MBH), thereby limiting the direct stimulatory effect of this hormone on the liver. The suppression required activation of protein kinase A in the MBH and intact vagus nerves. It also occurred independently from changes in circulating glucose, insulin or glucagon. Remarkably, glucagon's central inhibitory effect on glucose production was defective in high fat-fed rats, suggesting that this negative feedback loop may have regulatory value and that its absence may contribute to the hyperglycemia associated with obesity, diabetes or both.
Despite being discovered nearly 90 years ago, glucagon has had a controversial history 2,3 . It was not until the last few decades that its role in coupling hepatic glucose production to the body's needs during fasting, exercise, infection, trauma and hypoglycemia was clearly established 4 . Likewise, recognition that the plasma concentration of glucagon is absolutely or relatively increased in individuals with type 1 or type 2 diabetes has occurred slowly. Even now, the extent of glucagon's contribution to the diabetic phenotype is debated 2, 3 .
The appreciation of the importance of glucagon in glucoregulation has been slowed, in part, by the lack of a highly specific assay for its measurement (in current assays ~50% of measured basal 'glucagon' is actually nonspecific, cross-reacting material). This means that changes in arterial plasma glucagon are more substantial than they might appear, an issue made worse by the fact that assessment of glucagon concentration in arterial plasma (where it is usually measured) underestimates its concentrations within the hepatic portal vein and liver sinusoids (where it acts). Skepticism about the physiological and pathophysiological role of this hormone was also triggered by the observation that the hepatic effect of a square-wave rise in glucagon wanes with time, such that after a few hours it seems to be gone 5 . In fact, however, if glucagon concentrations are then returned to baseline, there is a significant decrease in glucose production 5 . This indicates that the hormone is, in fact, still active, but with reduced potency. Numerous suggestions have been put forward to explain glucagon's evanescence 4 , including hyperglycemia, hyperinsulinemia, depletion of hepatic glycogen, decline in the amount of hepatic cAMP, phosphodiesterase activation and desensitization of hepatic glucagon receptors, but the cause remains unclear. Mighiu et al. 1 now shed new light on this important topic, drawing the conclusion that the downregulation of glucagon action at the liver is, at least in part, neural in origin and an important characteristic of glucagon's normal biology.
The authors' initial data 1 showed that infusion of glucagon directly into the MBH of rats inhibited glucose production in the presence npg or exercise). By contrast, in pathological conditions, it could become dysfunctional, thereby causing unwanted hyperglycemia.
It will be important going forward to further understand the signaling pathways and mechanisms (that is, glycogenolysis, gluconeogenesis or both) involved in brain glucagon's effect on the liver. Most importantly, however, it will be crucial to establish the physiological relevance of glucagon's effects in the brain in nonrodent species, particularly in humans. Although rodents offer powerful advantages over other species (for example, genetic manipulation and the precise delivery of hormones and compounds to specific brain nuclei), findings from such models often do not translate to humans [12] [13] [14] . With regard to glucose metabolism there are considerable differences between small and large animals. For example, glucose production is five-to tenfold greater in rodents, and glycogen depletion during fasting occurs more rapidly (several hours versus several days); thus they have a greater dependence on gluconeogenesis. Interestingly, hepatic denervation did not prevent evanescence of glucagon's hepatic effect in dogs 15 . Variation in the importance of liver innervation across species may also contribute to differences in insulin-mediated CNS regulation of hepatic glucose production 16 . If the observations of Mighiu et al. 1 extend to humans, it will be important to determine whether central glucagon resistance can explain any of the metabolic abnormalities associated with obesity, type 2 diabetes or both.
